Back to top
Search by company, common medicine name, or title of Risk Minimisation Material
For Healthcare Professionals
Inform health care professionals of the interference of Darzalex (daratumumab) with antibody screening and crossmatching
Card for patient's receiving Darzalex (daratumumab)- patient should carry this card while receiving treatment and for 6 months after treatment has ended.
For Healthcare Professionals
Information for Blood Banks on the intereference with Antiglobulin Test _blood typing
Patient alert card for male patients regarding the risk of embryo-foetal risks of exposure to women of child-bearing potential by semen associated with DAURISMO
For Healthcare Professionals
Deferasirox HCP Information Brochure
For Healthcare Professionals
Deferasirox Physician's Reference Checklist
For Healthcare Professionals
Deferasirox HCP Information Brochure
For Healthcare Professionals
Physicians reference checklist for dosing and monitoring
Please keep this document safe for future reference. This booklet is only intended for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.
For Healthcare Professionals
Checklist for dosing and biological monitoring
For Healthcare Professionals
This booklet provides detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment.
For Healthcare Professionals
Booklet with detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment
Booklet for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring of your treatment is important, and which medicines you can take while on deferasirox.
For Healthcare Professionals
Checklist for deferasirox dosing, dose adjustment and biological monitoring.
For Healthcare Professionals
minimise key adverse effects including medication errors during treatment
Booklet for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.
For Healthcare Professionals
Document highlights important information about requirements for Deferasirox (deferasirox) dosing, dose adjustment and biological monitoring.
For Healthcare Professionals
FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.
For Healthcare Professionals
Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals
FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals
This chart is mainly intended to assess the growth of school age boys. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years, with the WHO growth standard for children aged 2 years to 4 years. The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.
For Healthcare Professionals
A form template according to prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored.
For Healthcare Professionals
Checklist 1: checklist before prescribing Dexamfetamine sulfate 5 mg tablets
For Healthcare Professionals
Checklist 2: checklist for monitoring of ongoing therapy with Dexamfetamine sulfate 5 mg tablets.
For Healthcare Professionals
Consideration when ending treatment with Dexamfetamine sulfate 5mg Tablets
For Healthcare Professionals
This sheet provides additional information on Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate).
For Healthcare Professionals
A physician’s guide to prescribing Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate)
For Healthcare Professionals
This chart is mainly intended to assess the growth of school age girls. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years, with the WHO growth standard for children aged 2 years to 4 years. The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.
Information for parents and carers of patients prescribed with Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate)
For Healthcare Professionals
Educational materials for Dexamfetamine Sulfate 5mg tablets-PL 06464/3115 These materials have been designed to support you in the appropriate prescription and administration of Dexamfetamine Sulfate 5 mg tablets for the treatment of patients with ADHD. It is recommended that these materials be used in conjunction with the full prescribing information for the product.
For Healthcare Professionals
IV iron. Essential Prescription and Administration Information to Minimise the Risk of Serious Hypersensitivity Reactions
Intravenous (IV) Iron. Important Information for Patients about the Possible Risk of Serious Allergic Reactions with IV iron treatment (iron given by injection or infusion into a vein)
contains important safety information that patients need to be aware of before and during treatment with pamidronate disodium injections
For Healthcare Professionals
is a letter which should be viewable only by the HCP. It details the requirement for the dispensing pharmacist to discuss the contents of the Patient Reminder Card with the patient prior to dispensing.
For Healthcare Professionals
Safety information for the use of Dronedarone Aristo
For Healthcare Professionals
Prescriber checklist to be used in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.
For Healthcare Professionals
This short guide provides advice to healthcare professionals on the management of patients with advanced Parkinson’s disease who have started Duodopa therapy
For Healthcare Professionals
The information presented in these slides is provided as part of additional Risk Minimisation Program for Duodopa targeted to minimise: –Gastrointestinal (GI) events –Device-related risks –Procedure-related risks associated with the levodopa – carbidopa intestinal gel (LCIG) system
For Healthcare Professionals
This pocket guide provides a practical overview of the Duodopa system and potential complications related to the medication and its delivery system.
For Healthcare Professionals
This guide provides advice to healthcare professionals on how to minimise PEG-J tube related complications in patients receiving Duodopa therapy. It should be used in conjunction with any local guidance and the CADD-Legacy 1400 pump instruction manual.
For Healthcare Professionals
Important Additional Risk Minimisation Information for Healthcare Professionals Training for AbbVie Duodopa Specialists on LCIG System, PEG-J Placement, Aftercare and Minimisation of Procedure Complications
For Healthcare Professionals
FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products.
THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.
For Healthcare Professionals
Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme.
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme.
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme.
For Healthcare Professionals
FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme.
Are you a healthcare professional?
Skip to main content